anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Non-communicable diseases, previously thought of as a problem of high-income countries, now coexist in low- and middle-income countries, including the countries of origin for many refugees traveling to Europe. We aimed to describe the prevalence of risk factors for non-communicable diseases among refugees, asylum seekers, and subsidiary protection beneficiaries resettled or relocated in Portugal between 2015 and 2020 and compare these to the prevalence of risk factors in the 12 months before they left their country of origin. A cross-sectional study was conducted between 2019 and 2020 of all refugees, asylum seekers, and subsidiary protection beneficiaries attending a Lisbon, Portugal refugee center. Behavioral and biological risk factors were assessed using the WHO STEPwise modified questionnaire. A descriptive statistical analysis was conducted, which included 80 respondents, mainly men, with an average age of of 30.3 ± 9.8 years. The prevalence of several behavioral risk factors for non-communicable diseases among refugees, asylum seekers, and subsidiary protection beneficiaries was higher at the time of the study than in the 12 months before leaving the country of origin. Differences between men and women were noted in tobacco (49.1% vs. 25.9%) and alcohol use (43.4% vs. 18.5%) in the receiving country. Overweight and obesity also showed differences by gender (7.5% vs. 11.1% and 39.6% vs. 48.1%). The prevalence of suicidal ideation and suicidalplanning was high, and varied from 6.3% and 20% in the country of origin to 16.3% and 38.5% respectively in the receiving country, however the prevalence of suicide attempts was lower in the receiving country (66.7%) compared to the country of origin (100.0%). Information on health and social determinants is critical to identify priorities and increase access to access to gender-specific health and community level interventions, including mental health, to reduce risk factors associated with refugee relocation and resettlement.
Serious rash requiring hospitalization and discontinuation of treatment has been reported in association with the use of NUVIGIL (armodafinil) or modafinil (the racemic mixture of S- and R-enantiomers).

NUVIGIL has not been studied in pediatric patients in any setting and is not approved for use in pediatric patients for any indication.

In clinical trials of modafinil, the incidence of rash resulting in discontinuation was approximately 0.8% (13 per 1,585) in pediatric patients (age <17 years); these rashes included 1 case of possible Stevens-Johnson syndrome (SJS) and 1 case of apparent multi-organ hypersensitivity reaction/ Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) [see Warnings and Precautions (5.2)]. Several of the cases were associated with fever and other abnormalities (e.g., vomiting, leukopenia). The median time to rash that resulted in discontinuation was 13 days. No such cases were observed among 380 pediatric patients who received placebo.

Skin and mouth sores, blistering, and ulceration have been reported with modafinil and NUVIGIL in the postmarketing setting. Recurrence of signs and symptoms of serious dermatologic reactions following rechallenge has been reported in some cases.

Rare cases of serious or life-threatening rash, including SJS and toxic epidermal necrolysis (TEN), have been reported in adults and children in worldwide postmarketing experience with modafinil and NUVIGIL.

There are no factors, including duration of therapy, that are known to predict the risk of occurrence or the severity of rash associated with modafinil or NUVIGIL. In cases where the time to onset was reported, serious rash occurred 1 day to 2 months after initiation of treatment, but isolated cases of serious dermatologic reactions have been reported with symptoms beginning after prolonged treatment (e.g., 3 months). 

Although benign rashes also occur with NUVIGIL, it is not possible to reliably predict which rashes will prove to be serious. Accordingly, NUVIGIL should be discontinued at the first sign of rash, skin or mouth sores, or blistering or ulceration, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring.
Patients with certain disorders involving heart failure associated with preserved left ventricular ejection fraction may not benefit from digoxin treatment and may be particularly susceptible to adverse reactions when they are treated with digoxin. 

In patients with hypertrophic cardiomyopathy (formerly called idiopathic hypertrophic subaortic stenosis), the positive inotropic effect of digoxin leads to an increased subvalvular outflow gradient and therefore, may compromise cardiac output. Digoxin is rarely beneficial in patients with this condition. 

Chronic constrictive pericarditis is not generally associated with any inotropic defect, so heart failure of this etiology is unlikely to respond to treatment with digoxin. By slowing the resting heart rate, digoxin may actually decrease cardiac output in these patients. 

Digoxin as an inotropic agent is of limited value in patients with restrictive cardiomyopathies, although it has been used for ventricular rate control in the subgroup of patients with atrial fibrillation. In addition, patients with amyloid heart disease may be more susceptible to toxicity from digoxin at therapeutic levels because of an increased binding of digoxin to extracellular amyloid fibrils.
In this study, we investigated the protective role of Mzb1 in atherosclerotic plaque vulnerability. To explore the impact of Mzb1, we analyzed Mzb1 expression, assessed apoptosis, and evaluated mitochondrial function in atherosclerosis (AS) mouse models and human vascular smooth muscle cells (HVSMCs). We observed a significant decrease in Mzb1 expression in AS mouse models and ox-LDL-treated HVSMCs. Downregulation of Mzb1 increased ox-LDL-induced apoptosis and cholesterol levels of HVSMCs, while Mzb1 overexpression alleviated these effect. Mzb1 was found to enhance mitochondrial function, as evidenced by restored ATP synthesis, mitochondrial membrane potential, and reduced mtROS production. Moreover, Mzb1 overexpression attenuated atherosclerotic plaque vulnerability in ApoE-/- mice. Our findings suggest that Mzb1 overexpression regulates the AMPK/SIRT1 signaling pathway, leading to the attenuation of atherosclerotic plaque vulnerability. This study provides compelling evidence for the protective effect of Mzb1 on atherosclerotic plaques by alleviating apoptosis and modulating mitochondrial function in ApoE-/- mice.
A method of preparing morinda root-flavored partridge meat paste is disclosed. Morinda root and partridges are adopted as raw materials, and coralhead plant stem with leaves and asiatic cornelian cherry fruit are added to prepare the meat paste. Nutrition value of the morinda root and nutrition value of the partridges are fully utilized. The morinda root and the partridges are compatible with traditional Chinese medicines and are synergistic. The meat paste has functions of invigorating the spleen, tonifying the stomach, helping digestion and regulating middle energizers. The raw material morinda root is subjected to primary fermentation with sweet jiuqu, and therefore alcohol fragrance is added to a product, a finished product is mellow in flavor, has significant healthcare functions, is easy to store and can improve discomfort of persons with dyspepsia after long-term eating of the meat paste. The preparing process is simple and easy to implement. The meat paste meets market development requirements and can be produced in a large scale.
PURPOSE:To develop perfume compositions of various types and fancy, with which a sufficient sedative effect is imparted by using 1,3-dimethoxy-5- methylbenzene as the perfume modifier. CONSTITUTION:A perfume composition containing 0.01-30wt.% 1,3-dimethoxy-5- methylbenzene as a perfume modifier which can impart a sedative effect is provided. This composition may be optionally combined with auxiliary components to give a perfume fluid, a cologne, a skin care, a body rinse, an aromatic agent, a deodorant, a bath or the like. The amount of 1,3-dimethoxy-5- methylbenzene added to the perfume composition may be suitably determined according to the object of use, etc. When the amount of the perfume modifier used is 0.01wt.% or above, the perfume composition can show a sedative effect. Even when the modifier is contained in an amount of above 30wt.%, it cannot show a marked sedative effect. Therefore it is not desirable to add this modifier in an amount larger than that in consideration of the balance among the perfumes.
PURPOSE:To obtain a treating liquid used for treatment of atopic dermatitis, contact dermatitis, dropsy, ulcer, etc., or used to sanitary product by dissolving chitosan in an acetic acid solution and mixing humic acid into the solution. CONSTITUTION:The aimed treating liquid obtained by dissolving chitosan in an acetic acid solution and simultaneously mixing humic acid into the solution and capable of utilizing as remedy for skin, hair tonic, base agent for cosmetics, etc. Further, the treating liquid is used for sanitary product. Chitosan is hydrolyzed into an amino sugar which is called cosamin by dissolving chitosan into a solution of acetic acid and the resultant amino sugar cures dermatitis. Namely, the amino sugar recovers function of broken skin and proliferates skin and cures inflammation and rears hair from head part. Humic acid facilitate use of the treating liquid by removing offensive odor released from the acetic solution.
Of the 2484 patients treated with MOTEGRITY 1 mg or 2 mg once daily in 6 controlled trials of at least 12-week duration in patients with CIC, 15% were 65 years of age and over, and 5% were 75 years of age and over [see Clinical Studies (14)]. No overall differences in safety and effectiveness were observed between elderly and younger patients.

In an additional 4-week double-blind, placebo-controlled dose escalation study in 89 elderly nursing home residents with CIC (PRU-USA-26, NCT00627692), no unanticipated safety issues were identified.

Elderly subjects had higher prucalopride exposure compared to younger subjects. However, the effect of age on the pharmacokinetics of prucalopride appeared to be related to decreased renal function [see Clinical Pharmacology (12.3)]. Adjust the dosage in elderly patients based on renal function [see Dosage and Administration (2), Use in Specific Populations (8.6)].
Patients who meet inclusion criteria for a primary diagnosis of MDD, OCD, GAD, or Schizophrenia (n=90) and consent to treatment will be assigned two random stimulation sites in the left prefrontal cortex and receive 2 days of accelerated iTBS treatment at the first stimulation site. Patients will have a 2 month break before coming back for 2 days of accelerated iTBS treatment at the second stimulation site. Patients with schizophrenia will be offered to participate in a third arm of the trial using a schizophrenia-specific target. This arm will also include fMRI scans and behavioral testing pre- and post- aiTBS. There will be two days (6 hours total) of behavioral testing and MRI scanning before each stimulation session and two days (6 hours total) after each stimulation session. Participants will be given the option of completing the behavioral testing in one day, before and after stimulation sessions. All the patients will receive active stimulation, which will facilitate enrollment and eliminate ethical concerns about placebo treatment in vulnerable patient populations. All participants will be blinded to their target coordinates and scales will be administered by a blinded study staff.
The invention relates to a traditional Chinese medicine composition for treating deafness. The traditional Chinese medicine composition for treating deafness is prepared from vegetative Chinese herbal medicines. The traditional Chinese medicine composition is characterized in that raw medicines for preparation of active ingredients comprise 20 to 30g of magnetite, 15 to 25g of root of hairy asiabell, 10 to 20g of radix astragali, 10 to 20g of red sage root, 10 to 20g of radix polygoni multiflori preparata, 5 to 15g of white peony root, 5 to 15g of fructus psoraleae, 5 to 15g of aerial parts of epimedium, 5 to 15g of polygonatum rhizome and 5 to 15g of Chinese magnoliavine fruit. Through compatibility, the raw medicines supplement each other and thus the traditional Chinese medicine composition has effects of nourishing the liver and the kidney, boosting essence and blood, invigorating the spleen and moistening the lung, moistening the kidney and invigorating yang, relieving convulsion and calming the nerves, promoting blood circulation and removing blood stasis, cooling blood and eliminating carbuncle, eliminating vexation and relieving uneasiness of mind, etc. Through synergism of the effects, the traditional Chinese medicine composition can realize simultaneous treatment of principal and subordinate symptoms and does not have toxic and side effects. Through treatment on deafness, effects of nourishing the liver and the kidney, boosting essence and blood, moistening the kidney and invigorating yang, promoting blood circulation and removing blood stasis, and cooling blood and eliminating carbuncle are obtained, and thus the traditional Chinese medicine composition can be utilized for treatment of deafness caused by internal organ imbalance, qi-blood disharmony, channel and collateral impassability, etc.
Clinical resemblance is one the of main factors that preclude the success of any restoration. The use of conventional titanium implant abutment and ceramic restoration succeeded to prevail until now. New ceramic and polymer derivatives have been introduced such as hybrid ceramics, PEEK and PEKK. However, the low mechanical properties and the ease of breakage still limited them to certain clinical situations. Hybrid fixture-abutment combinations such as hybrid abutments and hybrid crowns proved to be highly efficient in the literature. But the technique sensitivity and the urge of high clinical and laboratory skills are obstacles that must be taken into consideration. This is the reason that finding esthetic modification of the conventional techniques seems reasonable. Masking the color of the underlying abutment appears to be a simple and easily achievable solution for having a highly esthetic implant supported prosthesis.

The importance of peri-implant soft tissues, whether esthetically or biologically, has been emphasized in literature. (4) Furthermore, achieving the desired esthetic outcome depends on simultaneously matching the proper esthetic criteria of the tooth and its supporting structures. (5) Esthetic failures in implant dentistry can be categorized as pink-tissue failures and white-tissue failures. (6) Pink esthetics include color, texture and level of peri-implant tissues (7), while white esthetics include color, shape and characterization of crown. (3) The mode of fabrication also influences the performance of the materials, where the use of press technology facilitates the construction of implant supported crowns, offering precision of fit, durability and esthetic materials application. (11)
A system and method for managing off-label drug use within a health care network is disclosed herein. The system includes a Health Information Exchange system for managing off-label drug use within a health care network. The health information exchange system may comprise one or more user interfaces. The one or more user interfaces may be accessed by one or more users via one or more user devices. Additionally, the health information exchange system may be connected with a user device and a provider device through a communication network. Furthermore, the system may comprise a group of components for managing off-label drug use within the health care network. The group of components may include a processor, interface(s), and a memory. The memory may include an off-label base module and an off-label safety module. The off-label base module may include a permission module, a correlation generator module, and a recommendation module.
Adults patients with mild asthma (18 to 65 years old), who are 'inhaled corticosteroid (ICS)'-naïve for minimum 60 days at Screening Visit will be enrolled in the study. The patients will be treated for 28 days. The primary endpoint will be assessed by a provocative concentration of methacholine that results in a 20% drop (PC20) in the first second forced expiratory volume (FEV1) as determined by methacholine challenge test. The pharmacokinetics (PK) endpoint, i.e. PK profile of budesonide in plasma, and pharmacodynamics (PD) endpoints, i.e. recording of symptom scores, use of reliever drugs as needed, biomarkers of airway inflammation and pulmonary function tests will be assessed during the study.
INTRODUCTION: The aim of this study was to evaluate the association between parity and the incidence rate of groin hernia repair in women.
METHOD: This study was based on two Swedish national registers, the Medical Birth Register (MBR), and the Swedish Hernia Register (SHR). The cohort constituted of women born between 1956 and 1983. Data on vaginal and cesarean deliveries were retrieved from the MBR. The birth and hernia registers were cross matched to identify hernia repairs carried out after deliveries.
RESULTS: A total of 1,535,379 women were born between 1956 and 1983. Among these, 1,417,237 (92.3%) were registered for at least one birth. The incidence rate for Inguinal Hernia Repair (IHR) and Femoral Hernia Repair (FHR) was 10.7 per 100,000 person-year and 2.6 per 100,000 person-year, respectively. Compared with women registered for one delivery, the incidence rate ratio for IHR was 1.31 (95% Confidence Interval: 1.23-1.40) among women registered for two deliveries, 1.70 (1.58-1.82) among women registered for ≥ 3 deliveries. Additionally, the incidence rate ratios were higher 1.30 (1.14-1.49) and 1.70 (1.49-1.95) for FHR among women with two and  ≥ 3 registered deliveries, respectively.
CONCLUSION: In the present cohort, higher parity was associated with a higher incidence of inguinal as well as FHRs.
PURPOSE:A sticklike powder cosmetic, e.g. sticklike antiperspirant powder, having  improved feeling of use, adhesion to the skin and shape retention, and containing  monoclinic magnesium stearate. CONSTITUTION:A sticklike powder cosmetic, e.g. a sticklike antiperspirant powder, deodorant powder, baby powder, shaving powder or eye shadow powder, prepared  by incorporating a powder base consisting of talc and kaolin and other desired constituents, e.g. a deodorant constituent such as a germicide, an antiperspirant and deodorant constituent, a perfume or coloring material, with 4wt% or more, preferably 6-12wt% monoclinic magnesium stearate, and press molding the mixture into a stick. The cosmetic can be prepared simply by pressing powdery and granular constituents, has improved shape retention and is capable of preventing the collapse of the stick during use thereof with certainty and high adhesiveness to the skin with a good feeling of use.
A tertiary amide-terminated dimer acid-based polyamide may be blended with a solvent to form a gel. The solvent may be flammable, and a wick may be added to the resulting gel so as to form a candle. Depending on the composition, the candle may be formed into a free-standing pillar, or may be better suited to being placed in a container. The solvent may be mineral oil. A solid coating may be placed around the candle, for advantages including to enhance the mechanical stability of the gelled body, and to eliminate the tendency of a gel to have an oily feel and to accept noticeable fingerprints. The solvent which, in combination with the tertiary amine-terminated dimer acid-based polymer forms a gel, may be or include a fragrance material. In one aspect, the article does not contain a wick, and is intended to function as a fragrance-releasing product.
The risk of early recurrent events after stroke remains high despite currently established secondary prevention strategies1. Risk is particularly high in patients with atherosclerosis, with more than 10% of patients experiencing early recurrent events1,2. However, despite the enormous medical burden of this clinical phenomenon, the underlying mechanisms leading to increased vascular risk and recurrent stroke are largely unknown. Here, using a novel mouse model of stroke-induced recurrent ischaemia, we show that stroke leads to activation of the AIM2 inflammasome in vulnerable atherosclerotic plaques via an increase of circulating cell-free DNA. Enhanced plaque inflammation post-stroke results in plaque destabilization and atherothrombosis, finally leading to arterioarterial embolism and recurrent stroke within days after the index stroke. We confirm key steps of plaque destabilization also after experimental myocardial infarction and in carotid artery plaque samples from patients with acute stroke. Rapid neutrophil NETosis was identified as the main source of cell-free DNA after stroke and NET-DNA as the causative agent leading to AIM2 inflammasome activation. Neutralization of cell-free DNA by DNase treatment or inhibition of inflammasome activation reduced the rate of stroke recurrence after experimental stroke. Our findings present an explanation for the high recurrence rate after incident ischaemic events in patients with atherosclerosis. The detailed mechanisms uncovered here provide clinically uncharted therapeutic targets for which we show high efficacy to prevent recurrent events. Targeting DNA-mediated inflammasome activation after remote tissue injury represents a promising avenue for further clinical development in the prevention of early recurrent events.
PURPOSE: A composition containing deoxyshikonin for preventing and treating obesity or lipid metabolic disorders is provided to effectively suppress adipocyte differentiation. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity or lipid metabolic disorders contains deoxyshikonin as an active ingredient. The metabolic disorders are selected among diabetes, hyperlipidemia, fatty liver, arteriosclerosis, hypertension, cardiovascular disease, and metabolic syndrome. Deoxyshikonin suppresses adipocyte differentiation. A health food for preventing obesity or lipid-related metabolic disorders or alleviating symptoms thereof contains deoxyshikonin as an active ingredient. [Reference numerals] (AA) Neutral lipid (absorbance); (BB) Normal; (CC) Control group; (DD) Deoxyshikonin